Stocks To Track: HP Inc. (HPQ), The Procter & Gamble Company (PG), Merck & Co., Inc. (MRK)

HP Inc. (HPQ) fell -0.38% during last trading as the stock lost $-0.06 to finish the day at $15.92 with about 12.56M shares changing hands, compared to its three month average trading volume of 11.73M. The $27.3B market cap company, which fluctuated between $15.89 and $16.03 during the day, currently situated 74.94% above its 52 week low of $9.95 and -2.99% away from its one year high of $16.41. The RSI of 68.27 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

HP Inc. provides products, technologies, software, solutions, and services to individual consumers, small- and medium-sized businesses, and large enterprises, including customers in the government, health, and education sectors worldwide. It operates through Personal Systems and Printing segments. The Personal Systems segment offers commercial personal computers (PCs), consumer PCs, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, media, solutions, and services, as well as scanning devices; and laserJet and enterprise, inkjet and printing, graphics, and 3D printing solutions. The company was formerly known as Hewlett-Packard Company and changed its name to HP Inc. in October 2015. HP Inc. was founded in 1939 and is headquartered in Palo Alto, California.

The Procter & Gamble Company (PG) dropped $-0.33 to close the day at a new closing price of $90.79, a -0.36% decrease in value from its previous closing price that moved the stock 17.5% above its 52 week low of $79.1. A total of 12.4M shares exchanged hands during the day compared with its three month average trading volume of 9.22M. The stock, which fluctuated between $90.54 and $91.12 during the day, currently situated -0.39% below its 52 week high. The stock is up by 6.9% in the past one month and up by 9.43% over the past three months. With a one year target estimate of $90.53 and RSI of 71.15, the stock still has upside potential, making it a sell for now.

The Procter & Gamble Company provides branded consumer packaged goods to consumers in North America, Europe, the Asia Pacific, India, the Middle East, Africa, and Latin America. The company’s Beauty segment offers hair care products comprising conditioners, shampoos, styling aids, and treatments; and antiperspirants and deodorants, personal cleansing, and skin care products. This segment markets its products under the Head & Shoulders, Olay, Pantene, Rejoice, Old Spice, Safeguard, and SK-II brands. Its Grooming segment provides blades and razors, pre- and post-shave products, and other shave care products, as well as appliances under the Braun, Fusion, Gillette, Mach3, Prestobarba, and Venus brands. The company’s Health Care segment offers toothbrushes, toothpaste, and other oral care products; and gastrointestinal, rapid diagnostics, respiratory, vitamins/minerals/supplements, and other healthcare products under the Oral-B, Crest, Prilosec, Vicks, Metamucil, Pepto Bismol, and Align brands. Its Fabric & Home Care segment provides fabric care products, including fabric enhancers, laundry additives, and laundry detergents; and home care products comprising air care, dish care, P&G professional, and surface care products under the Tide, Ariel, Downy, Gain, Cascade, Dawn, Febreze, Mr. Clean, and Swiffer brands. The company’s Baby, Feminine & Family Care segment offers baby care products, such as baby wipes, diapers, and pants; adult incontinence and feminine care products; and family care products, such as paper towels, tissues, and toilet papers. This segment markets its products under the Pampers, Always, Bounty, Charmin, Luvs, and Tampax brands. The company sells its products through mass merchandisers, grocery stores, membership club stores, drug stores, department stores, distributors, baby stores, specialty beauty stores, e-commerce, high-frequency stores, and pharmacies. The Procter & Gamble Company was founded in 1837 and is based in Cincinnati, Ohio.

Merck & Co., Inc. (MRK) had a active trading with around 12.35M shares changing hands compared to its three month average trading volume of 10.79M. The stock traded between $64.46 and $65.41 before closing at the price of $65.26 with 0.15% change on the day. The Kenilworth New Jersey 07033 based company is currently trading 36.82% above its 52 week low of $49.63 and -0.93% below its 52 week high of $65.87. Both the RSI indicator and target price of 63.14 and $68.55 respectively, lead us to believe that it should be put on hold over the coming weeks.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

 

Stocks Intraday Alert: Merck & Co., Inc. (MRK), Costco Wholesale Corporation (COST), The Charles Schwab Corporation (SCHW)

Merck & Co., Inc. (MRK) continued its upward trend with the stock climbing 1.37% or $0.89 to close the day at $65.66 on lower than average trading volume of 10.11M shares, compared to its three month average trading volume of 10.62M. The Kenilworth New Jersey 07033 based company has been outperforming the drug manufacturers – major companies by 3.4526% for last three months and its recent gains have pushed the stock slightly up 11.53% YTD, versus the drug manufacturers – major industry which is up 3.14% for the same period. The RSI of 67.8 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Costco Wholesale Corporation (COST) had a active trading with around 2.24M shares changing hands compared to its three month average trading volume of 2.18M. The stock traded between $171.55 and $173.64 before closing at the price of $173.63 with 0.97% change on the day. The Issaquah Washington 98027 based company is currently trading 26.36% above its 52 week low of $138.57 and 0.66% above its 52 week high of $173.64. Both the RSI indicator and target price of 75.17 and $175.46 respectively, lead us to believe that it could drop over the coming weeks.

Costco Wholesale Corporation, together with its subsidiaries, operates membership warehouses. It offers branded and private-label products in a range of merchandise categories. The company provides dry and packaged foods, and groceries; snack foods, candies, alcoholic and nonalcoholic beverages, and cleaning supplies; appliances, electronics, health and beauty aids, hardware, and garden and patio; meat, bakery, deli, and produces; and apparel and small appliances. It also operates gas stations, pharmacies, optical dispensing centers, food courts, and hearing-aid centers; and engages in the travel businesses. In addition, the company provides gold star individual and business membership services. As of August 28, 2016, it operated 715 warehouses, including 501 warehouses in the United States, Washington, District of Columbia, and Puerto Rico; 91 in Canada; 36 in Mexico; 28 in the United Kingdom; 25 in Japan; 12 in Korea; 12 in Taiwan; 8 in Australia; and 2 in Spain. Further, the company sells its products through online. The company was formerly known as Costco Companies, Inc. Costco Wholesale Corporation was founded in 1976 and is based in Issaquah, Washington.

The Charles Schwab Corporation (SCHW) traded within a range of $40.44 to $41.49 after opening the day at $40.69. The company has seen its stock increase in value by 4.75% so far this year. The stock was up close to 1.33% on light volume in last trading session and closed at $41.26 per share. After the recent gain, the stock is currently holding -2.97% below its 52 week high of $42.61 and 81.02% above its 12-month low of $23. The shares are up by over 14.59% in the last three months, and the RSI indicator value of 56.3 is neither bullish nor bearish, tempting investors to stay on the sidelines.

The Charles Schwab Corporation, through its subsidiaries, provides wealth management, securities brokerage, banking, money management, custody, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services. The Investor Services segment provides retail brokerage and banking services, retirement plan services, and other corporate brokerage services; and stock plan services, compliance solutions, and mutual fund clearing services, as well as engages in the off-platform sales business. The Advisor Services segment provides custodial, trading, and support services; and retirement and corporate brokerage retirement services. The company provides brokerage accounts with cash management capabilities; third-party mutual funds through the Mutual Fund Marketplace, including no-transaction fee mutual funds through the Mutual Fund OneSource service, which includes proprietary mutual funds, plus mutual fund trading, and clearing services to broker-dealers; exchange-traded funds (ETFs), including proprietary and third-party ETFs; and advice solutions, such as managed portfolios of proprietary and third-party mutual funds and ETFs, separately managed accounts, customized personal advice for tailored portfolios, and specialized planning and portfolio management. It also offers banking products and services, including checking and savings accounts, certificates of deposit, first lien residential real estate mortgage loans, home equity loans and lines of credit, and Pledged Asset Lines; and trust services comprising trust custody services, personal trust reporting services, and administrative trustee services. The company serves individuals and institutional clients in the United States, the Commonwealth of Puerto Rico, London, and Hong Kong. The Charles Schwab Corporation was founded in 1971 and is headquartered in San Francisco, California.

 

Trader’s Buzzers: Twenty-First Century Fox, Inc. (FOXA), Exxon Mobil Corporation (XOM), Merck & Co., Inc. (MRK)

Twenty-First Century Fox, Inc. (FOXA) traded within a range of $29.81 to $30.28 after opening the day at $30.19. The company has seen its stock increase in value by 6.67% so far this year. The stock was down close to -0.7% on light volume in last trading session and closed at $29.91 per share. After the recent fall, the stock is currently holding -5.8% below its 52 week high of $31.75 and 29.61% above its 12-month low of $23.33. The shares are up by over 8.92% in the last three months, and the RSI indicator value of 48.74 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Twenty-First Century Fox, Inc., together with its subsidiaries, operates as a diversified media and entertainment company in the United States, the United Kingdom, Continental Europe, Asia, Latin America, and internationally. It operates through Cable Network Programming; Television; Filmed Entertainment; and Other, Corporate and Eliminations segments. The company produces and licenses news, sports, movie, and general and factual entertainment programming for distribution primarily through cable television systems, direct broadcast satellite operators, telecommunications companies, and online video distributors. It also broadcasts network programming; and operates 28 broadcast television stations, including 11 duopolies in the United States. In addition, the company produces and acquires live-action and animated motion pictures for distribution and licensing in various formats and entertainment media, as well as produces and licenses television programming worldwide. Further, it offers video advertising services, including consumer engagement and on-demand marketing campaigns; and operates two San Francisco-Bay area television stations. The company was formerly known as News Corporation. Twenty-First Century Fox, Inc. was founded in 1922 and is headquartered in New York, New York.

Exxon Mobil Corporation (XOM) continued its upward trend with the stock climbing 0.83% or $0.68 to close the day at $82.52 on active trading volume of 8.76M shares, compared to its three month average trading volume of 11.37M. The Irving Texas 75039 based company has been outperforming the major integrated oil & gas group over the past 52 weeks, with the stock gaining 7.34%, compared to the industry which has advanced 32.82% over the same period. With RSI of 36.95, the stock should still continue to rise and get closer to its one year target estimate of $88.57, making it a hold for now.

Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. It also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and specialty products; and transports and sells crude oil, natural gas, and petroleum products. As of December 31, 2015, the company had approximately 35,909 gross and 30,114 net operated wells. Exxon Mobil Corporation was founded in 1870 and is headquartered in Irving, Texas.

Merck & Co., Inc. (MRK) dropped $-0.24 to close the day at a new closing price of $64.15, a -0.37% decrease in value from its previous closing price that moved the stock 37.16% above its 52 week low of $49.24. A total of 8.53M shares exchanged hands during the day compared with its three month average trading volume of 10.85M. The stock, which fluctuated between $63.96 and $64.57 during the day, currently situated -1.25% below its 52 week high. The stock is up by 4.09% in the past one month and up by 0.72% over the past three months. With a one year target estimate of $68.55 and RSI of 61.33, the stock still has upside potential, making it a hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

 

Stocks Under Review: Mylan N.V. (MYL), Merck & Co., Inc. (MRK), Texas Instruments Incorporated (TXN)

Mylan N.V. (MYL) continued its downward trend with the stock declining -0.51% or $-0.2 to close the day at $39.19 on active trading volume of 5.93M shares, compared to its three month average trading volume of 5.44M. The Hatfield Hertfordshire EN6 1AG based company has been underperforming the drugs – generic group over the past 52 weeks, with the stock losing -22.76%, compared to the industry which has dropped -3.74% over the same period. With RSI of 60.91, the stock should still continue to rise and get closer to its one year target estimate of $49.84, making it a hold for now.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Merck & Co., Inc. (MRK) grew with the stock adding 0.19% or $0.12 to close at $64.32 on active trading volume of 5.9M compared its three months average trading volume of 11.22M. The Kenilworth New Jersey 07033 based company operating under the Drug Manufacturers – Major industry has been trending up for the last 52 weeks, with the shares price now 35.06% up for the period and up by 9.26% so far this year. With price target of $0 and a 38.41% rebound from 52-week low, Merck & Co., Inc. has plenty of upside potential, making it a hold with a view buy.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Texas Instruments Incorporated (TXN) continued its downward trend with the stock declining -0.3% or $-0.23 to close the day at $75.95 on higher than average trading volume of 5.86M shares, compared to its three month average trading volume of 5.43M. The Dallas Texas 75243 based company has been outperforming the semiconductor – broad line companies by 10.6366% for last three months and its recent gains have pushed the stock slightly up 4.74% YTD, versus the semiconductor – broad line industry which is up 7.1% for the same period. The RSI of 54.33 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing. The Analog segment offers high volume analog and logic products for automotive safety devices, touch screen controllers, low voltage motor drivers, and integrated motor controllers; and power management products that include catalog and application-specific standard products to enhance the efficiency of powered devices using battery management solutions, portable power conversion devices, power supply controls, and point-of-load products. This segment also provides high performance analog products, such as high-speed data converters, amplifiers, sensors, high reliability products, interface products, and precision products; and silicon valley analog products, including power management, data converter, interface, and operational amplifier catalog analog products that are used in manufacturing various electronic systems. The Embedded Processing segment offers microcontroller products, which are systems with a processor core, memory, and peripherals to control a set of specific tasks for electronic equipment; processor products comprising digital signal and applications processors; and connectivity products consisting of electronic devices to connect and transfer data. The company also provides DLP products primarily used in projectors to create high-definition images; application-specific integrated circuits; calculators; and baseband products, as well as OMAP applications processors and connectivity products. It markets and sells its products through a direct sales force and distributors. Texas Instruments Incorporated was founded in 1930 and is headquartered in Dallas, Texas.

 

Trader Alert: Merck & Co., Inc. (MRK), Wal-Mart Stores, Inc. (WMT), CSX Corporation (CSX)

Merck & Co., Inc. (MRK) grew with the stock adding 1.01% or $0.65 to close at $64.94 on active trading volume of 9.07M compared its three months average trading volume of 11.29M. The Kenilworth New Jersey 07033 based company operating under the Drug Manufacturers – Major industry has been trending up for the last 52 weeks, with the shares price now 35.76% up for the period and up by 10.31% so far this year. With price target of $0 and a 39.75% rebound from 52-week low, Merck & Co., Inc. has plenty of upside potential, making it a hold with a view buy.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Wal-Mart Stores, Inc. (WMT) dropped $-0.1 to close the day at a new closing price of $66.4, a -0.15% decrease in value from its previous closing price that moved the stock 9.59% above its 52 week low of $62.35. A total of 9.04M shares exchanged hands during the day compared with its three month average trading volume of 8.92M. The stock, which fluctuated between $66.37 and $66.86 during the day, currently situated -11.06% below its 52 week high. The stock is down by -4.06% in the past one month and down by -3.96% over the past three months. With a one year target estimate of $74.05 and RSI of 41.18, the stock still has upside potential, making it a hold for now.

Wal-Mart Stores, Inc. operates retail stores in various formats worldwide. It operates through three segments: Walmart U.S., Walmart International, and Sam’s Club. The company operates discount stores, supermarkets, supercenters, hypermarkets, warehouse clubs, cash and carry stores, home improvement stores, specialty electronics stores, apparel stores, drug stores, convenience stores, and membership-only warehouse clubs; and retail Websites, such as walmart.com and samsclub.com. It offers grocery products, including meat, produce, natural and organics, deli and bakery, dairy, frozen foods, alcoholic and nonalcoholic beverages, floral and dry grocery, as well as consumables, such as health and beauty aids, baby products, household chemicals, paper goods, and pet supplies; and health and wellness products, which include pharmacy, optical services, clinical services, over-the-counter drugs, and other medical products. The company also provides electronics, toys, cameras and supplies, photo processing services, cellular phones, cellular service plan contracts and prepaid service, movies, music, video games, and books; stationery, automotive, hardware and paint, and sporting goods, as well as fabrics, crafts, and seasonal merchandise; apparel for women, girls, men, boys, and infants, as well as shoes, jewelry, and accessories; and home furnishings, housewares and small appliances, bedding, home decor, outdoor living, and horticulture products. The company also provides fuel and financial services and related products, including money orders, prepaid cards, wire transfers, money transfers, check cashing, and bill payment. In addition, it offers brand name merchandise, including hardgoods, softgoods, and selected private-label items, such as Member’s Mark. As of June 20, 2016, it operated 11,527 stores under 63 banners in 28 countries and e-commerce Websites in 11 countries. Wal-Mart Stores, Inc. was founded in 1945 and is headquartered in Bentonville, Arkansas.

CSX Corporation (CSX) shares were up in last trading by 1% to $47.26. It experienced lighter than average volume on day. The stock decreased in value by almost -0.48% over the past week and grew 27.76% in the past month. It is currently trading 21.1% above its 50 day moving average and 52.94% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -3.81% decrease in value from its one year high of $49.13. The RSI indicator value of 68.1, lead us to believe that it is a hold for now.

CSX Corporation, together with its subsidiaries, provides rail-based transportation services in the United States and Canada. The company offers rail services, as well as transports intermodal containers and trailers. It transports agricultural products, phosphates and fertilizers, food and consumer products, chemicals, automotive products, metals, forest products, minerals, and waste and equipment; and coal, coke, and iron ore to electricity-generating power plants, steel manufacturers, and industrial plants. The company also exports coal to deep-water port facilities. In addition, it offers intermodal transportation services through a network of approximately 50 terminals transporting manufactured consumer goods in containers in the eastern United States; drayage services, including the pickup and delivery of intermodal shipments; and trucking dispatch services. Further, the company serves the automotive industry with distribution centers and storage locations, as well as connects non-rail served customers through transferring products from rail to trucks, which includes plastics and ethanol. Additionally, it acquires, develops, sells, leases, and manages real estate properties. The company operates approximately 21,000 route mile rail network, which serves various population centers in 23 states east of the Mississippi River, the District of Columbia, and the Canadian provinces of Ontario and Quebec, as well as owns and leases approximately 4,500 locomotives. It also serves production and distribution facilities through track connections. CSX Corporation was founded in 1978 and is based in Jacksonville, Florida.

 

Stocks in Review: Merck & Co., Inc. (MRK), CVS Health Corporation (CVS), Bristol-Myers Squibb Company (BMY)

Merck & Co., Inc. (MRK) traded within a range of $62.53 to $64.21 after opening the day at $62.64. The company has seen its stock increase in value by 9.02% so far this year. The stock was up close to 3.35% on active volume in last trading session and closed at $64.18 per share. After the recent gain, the stock is currently holding -1.2% below its 52 week high of $65.46 and 38.11% above its 12-month low of $47.97. The shares are up by over 9.06% in the last three months, and the RSI indicator value of 66.46 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

CVS Health Corporation (CVS) continued its downward trend with the stock declining -4.07% or $-3.17 to close the day at $74.8 on light trading volume of 18.76M shares, compared to its three month average trading volume of 8.66M. The Woonsocket Rhode Island 02895 based company has been underperforming the health care plans group over the past 52 weeks, with the stock losing -20.03%, compared to the industry which has advanced 14.32% over the same period. With RSI of 31.42, the stock should still continue to rise and get closer to its one year target estimate of $87.95, making it a hold for now.

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services. This segment serves employers, insurance companies, unions, government employee groups, health plans, managed Medicaid plans and plans offered on public and private exchanges, other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS Pharmacy, CVS Specialty, Accordant, SilverScript, NovoLogix, Coram, Navarro Health Services, and Advanced Care Scripts names. As of December 31, 2015, it operated 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies and 5 mail order dispensing pharmacies, and 83 branches for infusion and enteral services. The Retail/LTC segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, and greeting cards, as well as provides photo finishing services. It operates 9,655 retail stores in 49 states, the District of Columbia, Puerto Rico, and Brazil primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy, and Drogaria Onofre names; online retail pharmacy Websites; and 32 onsite pharmacy stores, long-term care pharmacy operations, and retail health care clinics. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket, Rhode Island.

Bristol-Myers Squibb Company (BMY) gained $1.21 to close the day at a new closing price of $50.5, a 2.45% increase in value from its previous closing price that moved the stock 9.76% above its 52 week low of $46.01. A total of 18.59M shares exchanged hands during the day compared with its three month average trading volume of 12.23M. The stock, which fluctuated between $49.27 and $50.89 during the day, currently situated -33.63% below its 52 week high. The stock is down by -14.49% in the past one month and up by 0.07% over the past three months. With a one year target estimate of $59.06 and RSI of 40.35, the stock still has upside potential, making it a hold for now.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

 

Stocks Trend Analysis: Simon Property Group, Inc. (SPG), The Charles Schwab Corporation (SCHW), Merck & Co., Inc. (MRK)

Simon Property Group, Inc. (SPG) managed to rebound with the stock climbing 3.39% or $6.03 to close the day at $183.77 on active trading volume of 3.4M shares, compared to its three month average trading volume of 1.64M. The Indianapolis Indiana 46204 based company has been outperforming the reit – retail group over the past 52 weeks, with the stock gaining 1.13%, compared to the industry which has advanced 1.47% over the same period. With RSI of 53.46, the stock should still continue to rise and get closer to its one year target estimate of $212.6, making it a hold for now.

Simon Property Group, Inc. is an equity real estate investment trust. The firm invests in the real estate markets across the globe. It engages in investment, ownership, management, and development of properties. It primarily invests in regional malls, premium outlets, mills, and community/lifestyle centers to create its portfolio. Simon Property Group, Inc. was founded in 1960 and is based in Indianapolis, Indiana, with additional office in New York, New York.

The Charles Schwab Corporation (SCHW) retreated with the stock falling -1.41% or $-0.59 to close at $41.24 on light trading volume of 8.06M compared its three months average trading volume of 9.17M. The San Francisco California 94105 based company operating under the Investment Brokerage – National industry has been trending up for the last 52 weeks, with the shares price now 64.7% up for the period and up by 4.48% so far this year. With price target of $46 and a 93.07% rebound from 52-week low, The Charles Schwab Corporation has plenty of upside potential, making it a hold with a view buy.

The Charles Schwab Corporation, through its subsidiaries, provides wealth management, securities brokerage, banking, money management, custody, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services. The Investor Services segment provides retail brokerage and banking services, retirement plan services, and other corporate brokerage services; and stock plan services, compliance solutions, and mutual fund clearing services, as well as engages in the off-platform sales business. The Advisor Services segment provides custodial, trading, and support services; and retirement and corporate brokerage retirement services. The company provides brokerage accounts with cash management capabilities; third-party mutual funds through the Mutual Fund Marketplace, including no-transaction fee mutual funds through the Mutual Fund OneSource service, which includes proprietary mutual funds, plus mutual fund trading, and clearing services to broker-dealers; exchange-traded funds (ETFs), including proprietary and third-party ETFs; and advice solutions, such as managed portfolios of proprietary and third-party mutual funds and ETFs, separately managed accounts, customized personal advice for tailored portfolios, and specialized planning and portfolio management. It also offers banking products and services, including checking and savings accounts, certificates of deposit, first lien residential real estate mortgage loans, home equity loans and lines of credit, and Pledged Asset Lines; and trust services comprising trust custody services, personal trust reporting services, and administrative trustee services. The company serves individuals and institutional clients in the United States, the Commonwealth of Puerto Rico, London, and Hong Kong. The Charles Schwab Corporation was founded in 1971 and is headquartered in San Francisco, California.

Merck & Co., Inc. (MRK) managed to rebound with the stock climbing 0.91% or $0.56 to close the day at $61.99 on higher than average trading volume of 9.82M shares, compared to its three month average trading volume of 11.3M. The Kenilworth New Jersey 07033 based company has been outperforming the drug manufacturers – major companies by 6.1457% for last three months and its recent gains have pushed the stock slightly up 5.3% YTD, versus the drug manufacturers – major industry which is down -0.6% for the same period. The RSI of 56.06 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

 

Stocks Alert: Best Buy Co., Inc. (BBY), Merck & Co., Inc. (MRK), KeyCorp (KEY)

Best Buy Co., Inc. (BBY) retreated with the stock falling -3.89% or $-1.76 to close at $43.47 on active trading volume of 6.7M compared its three months average trading volume of 5.56M. The Richfield Minnesota 55423 based company operating under the Electronics Stores industry has been trending up for the last 52 weeks, with the shares price now 68.57% up for the period and up by 1.87% so far this year. With price target of $46.09 and a 74.19% rebound from 52-week low, Best Buy Co., Inc. has plenty of upside potential, making it a hold with a view buy.

Best Buy Co., Inc. operates as a retailer of technology products, services, and solutions in the United States, Canada, and Mexico. The company operates through two reportable segments, Domestic and International. Its stores provide consumer electronics, such as home theater, home automation, digital imaging, health and fitness, and portable audio products; computing and mobile phones, including computing and peripherals, networking, tablets, smart watches, and e-readers, as well as mobile phones comprising related mobile network carrier commissions; and entertainment products, such as gaming hardware and software, movie, music, technology toy, and other software products. The company’s stores also offer appliances, which include refrigeration and laundry appliances, dishwashers, ovens, coffee makers, blenders, etc.; and other products comprising snacks, beverages, and other sundry items. In addition, it provides services, such as consultation, design, delivery, installation, set-up, protection plan, repair, technical support, and educational services. The company offers its products through stores and Websites under the Best Buy, bestbuy.com, Best Buy Mobile, Best Buy Direct, Best Buy Express, Geek Squad, Magnolia Home Theater, Pacific Kitchen and Home, bestbuy.com.ca, bestbuy.com.mx, and Geek Squad brand names, as well as through call centers. As of January 30, 2016, it had approximately 1,200 large-format and 400 small-format stores. The company was formerly known as Sound of Music, Inc. Best Buy Co., Inc. was founded in 1966 and is headquartered in Richfield, Minnesota.

Merck & Co., Inc. (MRK) gained $0.55 to close the day at a new closing price of $61.75, a 0.9% increase in value from its previous closing price that moved the stock 32.88% above its 52 week low of $47.97. A total of 6.65M shares exchanged hands during the day compared with its three month average trading volume of 11.55M. The stock, which fluctuated between $61.3 and $61.99 during the day, currently situated -4.94% below its 52 week high. The stock is up by 3.28% in the past one month and up by 2.22% over the past three months. With a one year target estimate of $68.21 and RSI of 54.3, the stock still has upside potential, making it a hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

KeyCorp (KEY) shares were down in last trading by -0.81% to $18.3. It experienced lighter than average volume on day. The stock increased in value by almost 2.46% over the past week and fell -1.29% in the past month. It is currently trading 2.05% above its 50 day moving average and 34.23% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -2.5% decrease in value from its one year high of $18.77. The RSI indicator value of 54.15, lead us to believe that it is a hold for now.

KeyCorp operates as the bank holding company for KeyBank National Association that provides various retail and commercial banking services to individual, corporate, and institutional clients in the United States. The company’s Key Community Bank segment offers deposit and investment products; personal finance services and loans, including residential mortgages, home equity, credit cards, and various installment loans for individuals; deposits, investment and credit products, and business advisory services to small businesses; and financial, estate and retirement planning, and asset management services to high-net-worth clients. This segment also provides commercial lending, cash management, equipment leasing, investment and employee benefit programs, succession planning, access to capital markets, derivatives, and foreign exchange services to mid-sized businesses. Its Key Corporate Bank segment offers a suite of banking and capital market products, such as syndicated finance, debt and equity capital market products, commercial payments, equipment finance, commercial mortgage banking, derivatives, foreign exchange, financial advisory, and public finance, as well as commercial mortgage loans for middle market clients comprising consumer, energy, healthcare, industrial, public, real estate, and technology sectors. In addition, KeyCorp provides personal, securities lending, and custody services; access to mutual funds; treasury, investment banking, international banking, and investment management services; public retirement plans, and foundations and endowments plans; and financial services consisting of community development financing, securities underwriting, and brokerage, as well as merchant services. As of December 31, 2015, the company operated 966 retail banking branches and 1,257 automated teller machines in 12 states, as well as a telephone banking call center. KeyCorp was founded in 1849 and is headquartered in Cleveland, Ohio.

 

Stocks To Track: Gilead Sciences Inc. (GILD), Morgan Stanley (MS), Merck & Co., Inc. (MRK)

Gilead Sciences Inc. (GILD) climbed 2.36% during last trading as the stock added $1.66 to finish the day at $71.91 with about 14.03M shares changing hands, compared to its three month average trading volume of 9.84M. The $95.49B market cap company, which fluctuated between $70.72 and $72.34 during the day, currently situated 3.05% above its 52 week low of $69.78 and -28.98% away from its one year high of $103.1. The RSI of 43.68 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Morgan Stanley (MS) gained $1.13 to close the day at a new closing price of $43.86, a 2.64% increase in value from its previous closing price that moved the stock 111.11% above its 52 week low of $21.16. A total of 13.92M shares exchanged hands during the day compared with its three month average trading volume of 12.25M. The stock, which fluctuated between $42.96 and $43.9 during the day, currently situated -1.66% below its 52 week high. The stock is up by 2.5% in the past one month and up by 32.18% over the past three months. With a one year target estimate of $46.37 and RSI of 57.73, the stock still has upside potential, making it a hold for now.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The company’s Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; and corporate lending services, credit products, and investments and research services. Its Wealth Management segment offers various financial services and solutions covering brokerage and investment advisory services, market-making services in fixed income securities, financial and wealth planning services, annuity and insurance products, credit and other lending products, and banking and retirement plan services to individual investors, small-to-medium sized businesses, and institutions. The company’s Investment Management segment provides various investment strategies and products comprising asset management, including equity, fixed income, liquidity, alternatives, and managed futures products. This segment is also involved in merchant banking and real estate investing businesses. Morgan Stanley was founded in 1924 and is headquartered in New York, New York.

Merck & Co., Inc. (MRK) had a active trading with around 13.74M shares changing hands compared to its three month average trading volume of 11.53M. The stock traded between $60.76 and $61.38 before closing at the price of $61.08 with -0.21% change on the day. The Kenilworth New Jersey 07033 based company is currently trading 31.44% above its 52 week low of $47.97 and -5.98% below its 52 week high of $65.46. Both the RSI indicator and target price of 50.44 and $68.21 respectively, lead us to believe that it should be put on hold over the coming weeks.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

 

Stocks To Watch: Merck & Co., Inc. (MRK), LendingClub Corporation (LC), CF Industries Holdings, Inc. (CF)

Merck & Co., Inc. (MRK) traded within a range of $60.73 to $61.69 after opening the day at $61.59. The company has seen its stock increase in value by 3.97% so far this year. The stock was down close to -0.97% on light volume in last trading session and closed at $61.21 per share. After the recent fall, the stock is currently holding -5.77% below its 52 week high of $65.46 and 31.72% above its 12-month low of $47.97. The shares are up by over 0.78% in the last three months, and the RSI indicator value of 51.11 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

LendingClub Corporation (LC) continued its upward trend with the stock climbing 0.17% or $0.01 to close the day at $5.9 on light trading volume of 10.48M shares, compared to its three month average trading volume of 8.41M. The San Francisco California 94105 based company has been underperforming the credit services group over the past 52 weeks, with the stock losing -26.16%, compared to the industry which has advanced 28.% over the same period. With RSI of 59.62, the stock should still continue to rise and get closer to its one year target estimate of $6.38, making it a hold for now.

LendingClub Corporation, together with its subsidiaries, operates as an online marketplace that connects borrowers and investors in the United States. Its marketplace facilitates various types of loan products for consumers and small businesses, including unsecured personal loans, super prime consumer loans, unsecured education and patient finance loans, and unsecured small business loans. The company also offers investors an opportunity to invest in a range of loans based on term and credit characteristics. It serves investors, such as retail investors, high-net-worth individuals and family offices, banks and finance companies, insurance companies, hedge funds, foundations, pension plans, and university endowments. LendingClub Corporation was founded in 2006 and is headquartered in San Francisco, California.

CF Industries Holdings, Inc. (CF) gained $1.6 to close the day at a new closing price of $36.85, a 4.54% increase in value from its previous closing price that moved the stock 81.98% above its 52 week low of $20.77. A total of 10.46M shares exchanged hands during the day compared with its three month average trading volume of 5.93M. The stock, which fluctuated between $35.56 and $37.13 during the day, currently situated 1.2% above its 52 week high. The stock is up by 27.51% in the past one month and up by 43.8% over the past three months. With a one year target estimate of $29.07 and RSI of 71.36, the stock still has upside potential, making it a sell for now.

CF Industries Holdings, Inc. manufactures and distributes nitrogen fertilizers and other nitrogen products worldwide. The company operates through Ammonia, Granular Urea, UAN, AN, Other, and Phosphate segments. Its primary nitrogen fertilizer products include ammonia, granular urea, urea ammonium nitrate, and ammonium nitrate. The company also provides diesel exhaust fluid, urea liquor, nitric acid, and aqua ammonia as well as compound fertilizer product, such as nitrogen, phosphorus, and potassium fertilizer. It offers products primarily to cooperatives, independent fertilizer distributors, farmers, and industrial users. CF Industries Holdings, Inc. was founded in 1946 and is based in Deerfield, Illinois.